Collegium Pharmaceutical
COLL
242 hedge funds and large institutions have $1.1B invested in Collegium Pharmaceutical in 2025 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 77 increasing their positions, 98 reducing their positions, and 25 closing their positions.
235% more call options, than puts
Call options by funds: $617K | Put options by funds: $184K
28% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 25
2% more funds holding
Funds holding: 238 → 242 (+4)
1.43% more ownership
Funds ownership: 115.16% → 116.59% (+1.4%)
3% more capital invested
Capital invested by funds: $1.06B → $1.1B (+$31.5M)
21% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 98
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$19.9M |
| 2 |
Millennium Management
New York
|
+$14.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$11.2M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$5.72M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$52.7M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$5.02M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.38M |
| 4 |
Man Group
London,
United Kingdom
|
-$3.47M |
| 5 |
BlackRock
New York
|
-$3.1M |
COLL Hedge Fund Activity: Q1 2025 in Review
242 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2025, worth a combined $1.1B — up 3% from $1.06B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new COLL positions and 25 closed out — a net gain of 7 holders — while 77 added to existing stakes and 98 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $19.9M. The largest seller was Pacer Advisors, cutting an estimated $52.7M.
- 242 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2025, up from 238 in Q4 2024.
- Funds reported $1.1B of Collegium Pharmaceutical stock for Q1 2025, up 3% quarter-over-quarter.
- 32 funds opened new Collegium Pharmaceutical positions in Q1 2025 and 25 closed out, a net change of +7 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2025 was Rubric Capital Management (New York), an estimated $19.9M added.
- The largest Collegium Pharmaceutical seller in Q1 2025 was Pacer Advisors, an estimated $52.7M sold.
Based on aggregated 13F filings for Q1 2025.